| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|
|
topdog22
Senior |
13-Oct-2010 17:32
|
|
x 0
x 0 Alert Admin |
looks like a new shareholder came on board, appears to be Fidelity out of the USA: Name of Announcer: Kevin R. Sayer Designation: Company Secretary Broadcast date: 13-Oct-2010 Broadcast time: 13:26:53 Price sensitivity : No Contact No.: 62135777 Submission date: 13/10/2010 Submission time: 1:26:12 PM Date of notice to issuer (Part I): 13/10/2010 Shareholder Type (Part I): Substantial Shareholder Name of Shareholder Type (Part I): (1) FMR LLC; FMR is "semper fidelis" (ever faithful) to its core business. The financial services conglomerate, better known as Fidelity Investments, is one of the world's largest mutual fund firms. Serving more than 20 million individual and institutional clients, Fidelity manages nearly 500 funds and has approximately $1.5 trillion of assets under management. It also operates a leading online discount brokerage and has more than 100 investor centers in the US and Canada, as well as locations in Europe and Asia. The founding Johnson family controls FMR; Abigail Johnson, CEO Ned Johnson's daughter and perhaps his successor (not to mention one of the richest women in America), is the company's largest single shareholder. (2) FIL Limited; Since 1969, FIL Limited has been providing asset management services to institutional investors with proven and repeated success. Fidelity offers a range of ... and (3) Edward C. Johnson 3d Edward C. Johnson 3d Mr. Johnson is Chairman of the Board of Trustees. Mr. Johnson serves as President (2006-present), Chief Executive Officer, Chairman, and a Director of FMR Corp.; Chairman and a Director of FMR; Chairman and a Director of Fidelity Research & Analysis Company (FRAC); Chairman and a Director of Fidelity Investments Money Management, Inc.; and Chairman (2001-present) and a Director of FMR Co., Inc. In addition, Mr. Johnson serves as Chairman and Director of Fidelity International Limited (FIL). Notice: Notice of a New Substantial Shareholder's interest. Shareholder Type (Part II): Deemed Interest Date of change of: 11/10/2010 Name of Registered Holder: Please see below footnote Circumstance(s) giving rise to the interest or change in interest: Open Market Purchase Details: The substantial shareholders are deemed to have an interest, by virtue ofSection 7(4) of the Companies Act, Chapter 50 of Singapore, in shares acquiredby the Registered Holders as listed in footnote below. Instrument Type I: No. of [Instrument Type] held before the change: 52,012,000 As a percentage of issued share capital: 4.80 Instrument Type II: Shares No. of Instrument Type II which are subject of this notice: 6,115,000 As a percentage of issued share capital: 0.56 Amount of consideration (excluding brokerage and stamp duties) per share paid orreceived: 1.09 Instrument Type III: Shares No. of N.A. held after the change: 58,127,000 As a percentage of issued share capital: Shareholder Type III: Date of change of ShareholderType III: The change in the percentage level (From): The change in the percentage level (To): Circumstance(s) giving rise to the interest or change interest: Details: A statement of whether the change in the percentage level is the result of atransaction or a series of transactions: Shareholder Type IV: Substantial Shareholder No. of shares held before the change (Direct): 0 No. of shares held before the change (Deemed): 52,012,000 As a percentage of issued share capital (Direct): 0 As a percentage of issued share capital (Deemed): 4.80 No. of shares held after the change (Direct): 0 No. of shares held after the change (Deemed): 58,127,000 As a percentage of issued share capital (Direct): 0 As a percentage of issued share capital (Deemed): 5.36 Footnotes: Name of Registered Holders are:FID INFORMTN TECH CENTRAL FDFID FDS - ASEAN POOLFID FDS - PACIFIC POOLFID FDS - SINGAPORE POOLFA TECHNOLOGY FUNDFA INT SOUTH EAST ASIA SUBFIJ IT JPN ASIA GROWTH MOTHERFID KOREA ASEAN EQ IT MTHRFID PACIFIC BASIN FUNDSELECT TECHNOLOGYVIP TECHNOLOGY PORTFOLIOIn this notification, the percentage of shareholding is expressed based on1,083,574,304 ordinary shares as at 13 October 2010. ReplyReply AllMove...InboxGo to Previous message | Go to Next message | Back to Messages Select Message EncodingASCII (ASCII)Greek (ISO-8859-7)Greek (Windows-1253)Latin-10 (ISO-8859-16)Latin-3 (ISO-8859-3)Latin-6 (ISO-8859-10)Latin-7 (ISO-8859-13)Latin-8 (ISO-8859-14)Latin-9 (ISO-8859-15)W. European (850)W. European (CP858)W. European (HPROMAN8)W. European (MACROMAN8)W. European (Windows-1252)Armenia (ARMSCII-8)Baltic Rim (ISO-8859-4)Baltic Rim (WINDOWS-1257)Cyrillic (866)Cyrillic (ISO-8859-5)Cyrillic (KOI8-R)Cyrillic (KOI8-RU)Cyrillic (KOI8-T)Cyrillic (KOI8-U)Cyrillic (WINDOWS-1251)Latin-2 (852)Latin-2 (ISO-8859-2)Latin-2 (WINDOWS-1250)Turkish (ISO-8859-9)Turkish (WINDOWS-1254)Arabic (ISO-8859-6, ASMO-708)Arabic (WINDOWS-1256)Hebrew (856)Hebrew (862)Hebrew (WINDOWS-1255)Chinese Simplified (GB-2312-80)Chinese Simplified (GB18030)Chinese Simplified (HZ-GB-2312)Chinese Simplified (ISO-2022-CN)Chinese Simplified (WINDOWS-936)Chinese Trad.-Hong Kong (BIG5-HKSCS)Chinese Traditional (BIG5)Chinese Traditional (EUC-TW)Japanese (SHIFT_JIS)Japanese (EUC-JP)Japanese (ISO-2022-JP)Korean (ISO-2022-KR)Korean (EUC-KR)Thai (TIS-620-2533)Thai (WINDOWS-874)Vietnamese (TCVN-5712)Vietnamese (VISCII)Vietnamese (WINDOWS-1258)Unicode (UTF-7)Unicode (UTF-8)Unicode (UTF-16)Unicode (UTF-32) |
| Useful To Me Not Useful To Me | |
|
allright
Senior |
13-Oct-2010 14:22
|
|
x 0
x 0 Alert Admin |
I dont know much about the market and i dont know Mr Lu personally but I am sure he is passionate about his company and will only sell because it will benefit shareholders. Lets wait for the conference call this afternoon after 5. He has been a very good and responsible chairman all these while. I have faith in his decision |
| Useful To Me Not Useful To Me | |
|
|
|
|
investor
Senior |
13-Oct-2010 14:07
|
|
x 0
x 0 Alert Admin |
For info. FMR purchased 6.115m shares of Biosensors at 1.09 on Monday, rasing their stake to 5.36 %, making them a substantial shareholder. (announcement in SGX). Not a call to buy/sell. |
| Useful To Me Not Useful To Me | |
|
XiaoMaGe888
Senior |
13-Oct-2010 11:20
|
|
x 0
x 0 Alert Admin |
DBS expects rise in M&A activity in Singapore Merger & acquisition activity involving Singapore companies expected to increase as sellers now more willing to negotiate following improved stock valuations, says DBS Vickers.
Notes buyers encouraged by better visibility of Singapore companies as worst of global crisis now over; “in addition to growth, Singapore companies are sitting on high net cash with 65% of them capable of generating free cash flow.” Notes Singapore firms sitting on $146.5 billion of net cash, thanks to capex discipline, capital restructuring in last 2 years. Says private equity firms now in fund raising mode, getting ready to invest from next year.
Tips companies in consumer, oil & gas, technology sectors as potential targets, including Asiatravel.com (5AM.SG), Hi-P (H17.SG), Meiban (M24.SG), Mermaid Maritime, (DU4.SG), JES (EG0.SG), Biosensors (B20.SG), OKP (5CF.SG), Wheelock Properties (M35.SG).
|
| Useful To Me Not Useful To Me | |
|
topdog22
Senior |
13-Oct-2010 10:37
|
|
x 0
x 0 Alert Admin |
NOMURA SECURITIES LATEST REPORT �� ActionHony Capital has emerged as the largest shareholder in BIG following the purchase of a 29.47% stake from seven vendors, including Mr Lu Yoh Chie, who will remain Chairman. While the divestment by Mr Lu at has created some uncertainty, the emergence of Hony Capital, a respected private equity firm, as a strategic shareholder should provide comfort to shareholders. Reiterate BUY. �� CatalystsContinued momentum in its forthcoming results, the potential value-unlocking of its 50% stake in domestic drug-eluting stent (DES) supplier in China, JWMS, and Japan’s approval of Terumo’s Nobori, whose technology is licensed from BIG. Anchor themes The US$5bn DES industry is one of the most profitable segments in the medical technology space, with market-share changes driven by innovation. Start-ups like
New strategic shareholder �� Chairman divests entire 18% stake Founder and Chairman Mr Lu Yoh Chie divested his entire stake in the company for S$174mn (S$0.88/share). While this came as a surprise, we believe that discussions have been going on for some time. Mr Lu will, however, remain as Chairman to provide continuity and we understand that there will be no changes to management. �� Hony Capital linked to Legend Holdings in China The advent of Hony Capital as the largest shareholder with a 29.47% stake is positive for the group, in our view; Hony has an established record of investing in promising companies in China, including China Glass Holdings and CSPC Pharmaceutical Group. We believe Hony will want to maintain the current management’s strong execution record and take the group forward, especially given BIG’s strong presence in China via its 50% stake in JWMS. With an established record in China, Hony Capital can assist BIG to maximise its 50% stake in JWMS, in our view. �� Maintain BUY — momentum to continue, in our view In spite of the divestment by the Chairman, BIG continues to be attractive given its strong revenue growth momentum in Europe, its strong market position in China and accelerating royalties from Terumo. In addition, recent trial data for its next-generation BioFreedom stent is encouraging and may allow BIG to address the US market at a later stage. The share price has pulled back slightly on news that the Chairman had sold his stake. However, we believe BIG has moved beyond the start-up phase and has the management team, technology and now a new strategic shareholder to help it grow further. Maintain BUY. |
| Useful To Me Not Useful To Me | |
|
|
|
|
topdog22
Senior |
13-Oct-2010 10:30
|
|
x 0
x 0 Alert Admin |
I agree with Infancy Bird. Terumo is well on its way to receive Japan approval of BIG products and I believe they are required to share clinical results enabling BIG to piggyback on their approval. I think share price may increase quickly as most private equity firms have relationships with global investment / mutual funds that will follow Hony. These firms will seek to capture the value difference between BIG and Microport and may perfer to have their investment in Singapore. Denominated in Singapore Dollars - a stable currency - rather than Hong Kong in HK$ especially since US and Europe is pressuring China to revalue its currency. |
| Useful To Me Not Useful To Me | |
|
infancybird
Senior |
13-Oct-2010 10:07
|
|
x 0
x 0 Alert Admin |
This is my view on future of BIG. China and Japan approval is just a matter of time if BIG stent can continue to produce favourable results over the other European counterpart. The latter is much more expensive than the former and this definitely favour BIG. As topdog said correctly, Hony capital thru its parent Legend Capital( has Chinese State interest) will exert very positive and powerful influence in the future growth of BIG in China /HK. This hurdle has been solve with Hony becoming the major stake holder.Now the next interestig catalyst is possible dual listing of BIG in HK which seems to have investor with better knowledge and taste for Stent Coy.If using Micoport IPo as a guide, listing of BIG (help by Hony/Legend)will easily push price of BIG to SGD $1.50-1.80. I am waiting for that day to happen and prepare patiently to ride this Big Wave. |
| Useful To Me Not Useful To Me | |
|
topdog22
Senior |
13-Oct-2010 09:54
|
|
x 0
x 0 Alert Admin |
I am uncertain whether I am justifiably paranoid BUT: BIG has multiple long term globally recognized studies proving it’s technology, stent efficacy and product safety: These studies prove BIG products superior to JNJ & Boston Scientific: Microport & JWMs do not have the same globally recognized long term clinical studies proving product efficacy or superiority: Chinese Health Authority approved JNJ, Boston Scientific, Microport and JWMS. China Health Authority did not BIG stents even though BIG stents proven superior China government did not allow BIG to acquire all of JWMS NOW China Company with significant investments from the China Government buys 29%+ of BIG China has shown market protection in other areas. I wonder when China market approval will be granted??? Once again, I can not see anything negative about the Hony investment |
| Useful To Me Not Useful To Me | |
|
|
|
|
allright
Senior |
13-Oct-2010 08:41
|
|
x 0
x 0 Alert Admin |
Thank You topdog22 . Forgot he has share options etc. This is an exciting new era for Biosensors. Tip top123 and infancybird, great research. |
| Useful To Me Not Useful To Me | |
|
tiptop123
Member |
12-Oct-2010 22:33
|
|
x 0
x 0 Alert Admin |
Hony’s 2003 debut fund was a US dollar-denominated $38 million pool sponsored single-handedly by Legend. The fund did well and successor offerings followed quickly, with the firm soon looking to bring in third parties. Fund Ⅱ closed in September 2004 on $88 million and included commitments from Goldman Sachs, Sun Hung Kai and Temasek. Fund Ⅲ raised $580 million in 2006. 2008 saw Hony Garner $1.4 billion for yet another vehicle. A cast of international blue-chip LPs invested, including CalSTRS, the endowments of Stanford and Notre Dame universities, Rothschild, Pantheon, Partners Group, Squadron Capital, Asia Alternatives, Temasek and Goldman, Legend is a large investor in all four funds and owns a piece of Hony’s management company. The firm’s operating managers own the balance. Also in 2008 Hony broke new fundraising group by establishing an RMB-denominated fund exclusively for Chinese public sector institutions. It raised RMB 5 billion ($732 million) from a handful of handpicked state investors, including China’s giant Social Security Fund (SSF). In total, the firm’s asset under management now stand at $2.8 billion, of which $1.8 billion is available for new investment. In a market still getting to know private equity as a source of corporate funding, it is a considerable war chest. |
| Useful To Me Not Useful To Me | |
|
topdog22
Senior |
12-Oct-2010 21:57
|
|
x 0
x 0 Alert Admin |
allright wrote: "Does this mean Mr Loh has sold off all his holdings?What does this mean for the company?" I personally see this transition as a good thing for all shareholders. Allright, I would not worry about Mr Loh as I am certain he still has many millions of shares and share options not to mention the $160M, he just received. Past management teams have done a good job in developing and positioning leading edge products and technologies: But they have not been able to capitalize on this to the benefit of shareholders. Hony Capital seems to be able to bring that expertise to the table. Based on Microport and other peers it would not surprise me to see BIG trading in the $1.40 - $1.70 range in the near future. |
| Useful To Me Not Useful To Me | |
|
JustForFun
Member |
12-Oct-2010 18:01
|
|
x 0
x 0 Alert Admin |
Report from DBSV on M&A : BIG returns from stent • BIG has a leading technology that is capable of developing products that has competitive advantage in the market. • BIG’s is developing next generation technology while its competitors are playing catch up. • We believe BIG is positioned to attain good market share growth going forward with its market leading products. • BIG could be a prime target for take-over for its leading technology and product innovation. Worthy takeover target with its leading technology product innovations. We believe BIG is a worthy takeover target as it is technologically more advanced than its competition. BIG’s biodegradable polymer drug eluting stent (DES) is one generation ahead of its competition and has been tested to be safer and more effective than its competitors. We believe such superior product and technological advantage will position BIG to gain market share going forward. Could be coveted by global strategic players for the technology. Acquisitions are common in the Medtech space, and BIG could be coveted by strategic players such as Terumo or key big four competitors such Johnson and Johnson, Medtronic, Boston Scientific and Abbott Labs for its advanced technology. If any serious deal were to be done, we believe that the acquisition will be for BIG’s technological know how, possibly by strategic acquiror. BIG’s takeover story is more likely now since an unknown party named Autumn Eagle has emerged as its largest shareholder after purchasing an interest worth 29.47% from seven vendors. Offers more value than its Asian peers. We believe BIG offers more value than its Asian peers due to its technological strength and valuation discount to its Asian peers. BIG is currently trading at 22x prospective PE, a discount to its Asian peers of 36x. |
| Useful To Me Not Useful To Me | |
|
|
|
|
OddEye
Member |
12-Oct-2010 17:58
|
|
x 0
x 0 Alert Admin |
Stock looks good and is definitely on my buy list. Waiting for them to drop lower |
| Useful To Me Not Useful To Me | |
|
infancybird
Senior |
12-Oct-2010 16:14
|
|
x 1
x 0 Alert Admin |
Hony Capital: The Early-Mover AdvantageBy (TheAsset.com) Updated:2010-6-18 Print In recent years, a wave of renminbi-denominated private equity funds has created opportunities both for investors hoping to diversify investments and for companies in need of growth capital. Hony Capital , the private equity arm of Lenovo’s parent Legend Holdings, believes renminbi funds will fuel the growth of the domestic capital market. Hony Capital, founded in 2003, is one of earliest domestic private equity funds in China. It has emerged as one of the major players in the industry by successfully investing in a number of state-owned and privately-owned enterprises, as well as taking some of them public, such as Hong Kong-listed Digital China and New York-listed Simcere Pharmaceutical Group. After successfully closing four US dollar funds in five years, Hony Capital became a pioneer in renminbi funds by raising 5 billion renminbi (US$731 million) from a handful of Chinese institutional investors in 2008, including China’s National Social Security Fund (NSSF), Bank of China and China Development Bank. With assets under management currently of over US$2.8 billion, Hony Capital holds a portfolio of 25 investments. |
| Useful To Me Not Useful To Me | |
|
infancybird
Senior |
12-Oct-2010 15:48
|
|
x 0
x 0 Alert Admin |
HONY CAPITAL WILL HELP BIOSENSOR TO BE LISTED IN HONGKONG OR USA BASE ON THEIR EXTENSIVE EXPERIENCE IN IPO. READ THE FOLLOWING LEGEND CAPITAL (INTEREST IN LENOVO AND DIGITAL CHINA) IS RELATED TO HONY CAPITAL Founded in April 2001, Legend Capital is an independent venture capital subsidiary of Legend Holdings Ltd. focused on driving high-growth ventures with their operations substantially based in China or on markets related to China. Managing up to US$700 million across four funds under management, Legend Capital invests in early stage information technology applications and services providers, outsourcing and professional services providers, infrastructure including system components / materials suppliers, and health care as well as selected growth stage companies in industries of consumer goods, clean technologies and equipment manufacturing. Our bite size is between 5 million and 20 million USD per investment. We typically act as the lead or co-lead investor. LC funds have invested over 70 portfolio companies. Successful investments include Joyo.com (acquired by Amazon.com), SinoCom Software Group Ltd. (0299.HK), Solarfun Power Holdings (Nasdaq: SOLF), Spreadtrum Communications Inc. (Nasdaq:SPRD), China Sunshine Paper (2002.HK), VanceInfo Tech (NYSE: VIT), Eyang Group (0117. HK) and iFlyTek (002230.SZ). Legend Capital provides its portfolio companies with extensive business resources to assist in business development, company image building, and other critical company building activities in the China market. Please visit: www.legendcapital.com.cn Chairman: Liu Chuanzhi CEO: Zhu Li'nan Raycom Real Estate was incorporated on June 11th 2001 as the wholly owned subsidiary of Legend Holdings dedicated to real estate investment and development. Back to 1994, Raycom has started to accumulate real estate experience, when it operated under the name of Legend Industrial Co. Ltd.and built up Lenovo Science & Technology Park - Dayawan in Guangdong Huiyang. Afterwards, the company expanded into commercial real estate, and launched construction of Lenovo Shenzhen R&D Center, Digital China Software Development Center, and Raycom Info Tech Park Tower A and C. In 2003, the company officially penetrated into residential development segment and established regional operations across the country. During the past years, Raycom has maintained strong and stable growth momentum, and formed nationwide strategic coverage in Beijing, Tainjin, Chongqing, Wuhan, Changsha, Hefei, Yixing and multiple cities in Jiangxi. Its offerings vary from apartment building, garden house, to villas, and have received high popularity and several heavyweight awards. Raycom’s current business segments are focused on property development and property holding and management. With over 10 regional subsidiaries, 600 staff, and assets valued at 100 mn on hand, Raycom has risen to the top rank of property developers in China. Please visit: www.raycomchina.com Chairman: Liu Chuanzhi President: Chen Guodong HONY CAPITAL Founded in 2003, Hony Capital is among China’s leading domestic private equity firms. Hony Capital is a China-focused middle-market private equity firm, employing a “value creation” investment philosophy to increase the financial performance and value of its portfolio companies. With over US $2.8 billion in assets under management across five funds, Hony Capital primarily focuses on construction materials, pharmaceuticals, construction machinery and consumer goods and retail industries. Hony’s secondary industry focus is on media and entertainment, financial services, and energy and resources. Hony’s two business models are: 1) to participate in Chinese SOE restructuring and 2) to make growth capital investments in rapidly-growing Chinese private companies. Hony Capital is sponsored by Legend Holdings, one of the most successful and respected companies in China. During the past twenty years Legend has built such leading enterprises as Lenovo and Digital China, which are both publicly traded in Hong Kong. Please visit: www.honycapital.com Chairman: Liu Chuanzhi CEO: John H.Zhao |
| Useful To Me Not Useful To Me | |
|
infancybird
Senior |
12-Oct-2010 15:35
|
|
x 0
x 0 Alert Admin |
Since 2003, Hony Capital has invested in dozens of enterprises in Jiangsu, Guangdong, Zhejiang and Hunan. In 2009, the total investments in fixed assets reached RMB 196.7 billion, with an overall sale of RMB 133.9 billion and a total pre-tax profit of RMB 7.8 billion, through which, the enterprises offer more than 150,000 job opportunities. 投资案例地图
www.chinaglassholdings.comChina Glass Holdings Limited
China Glass is one of the most efficient manufacturers of flat glass in China. In January 2004, Hony Capital invested in China Glass. In June 2005, with the help of Hony Capital, China Glass successfully launched its initial public offering on HKEX.
www.boloni.com.cnKebao Boloni Group
Kebao Boloni is a leading high-end integrated furnishings designer and producer in China. Boloni offers customers a total home-décor solution, providing kitchen and bathroom furnishings and interior door and wall systems. In March 2005, Hony Capital invested in Kebao Boloni. China’s leading high-end kitchen & bath appliances & fixtures producer.
www.simcere.comSimcere Pharmaceutical Group
Simcere is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer drug Endu in the rapidly growing China market. The company currently manufactures and sells more than 50 pharmaceutical products and is the exclusive distributor of three additional pharmaceutical products marketed under its own brand name. In September 2005, Hony Capital invested in Simcere. In April 2007, with the help of Hony Capital, Simcere sucessfully launched its initial public offering on the NYSE, which was the first Chinese Pharmaceutical enterprise listing on NYSE.
www.zoomlion.comChangsha Zoomlion Heavy Industry Science & Technology Development Co., Ltd
Zoomlion (000157. SZ) is a leading construction and mining equipment manufacturer globally and the No.1 player in China market. The company is engaged in researching and manufacturing the key machineries for national infrastructural construction. In September 2008, Zoomlion teamed with Hony Capital, Goldman Sachs and Mandarin Capital Partners to acquire 100% equity stake of Compagnia Italiana Forme Acciaio S.P.A.. In May 2006, Hony Capital invested in Zoomlion.
www.jushi.comJushi Group Co Ltd.
Jushi Group is the largest fiberglass manufacturer worldwide, a subsidiary company of China Fiberglass Group (600176. SH) who owns 51% of Jushi’s equity stake. Its products are sold to over 30 provinces in China and exported to nearly 60 countries and regions including North America, Middle East, Europe, Southeast Asia and Africa. In January 2007, Hony Capital invested in Jushi Group.
www.e-cspc.comCSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an oversized domestic pharmacy company with its output of Vitamin C, Penicillin industrial salt and 7-aminocephalosporanic acid (7-ACA) ranking the first in the world. The output of Antibiotics produced by CSPC Pharma is taking the lead in China, it is a subsidiary under China Pharma（1093.HK), listed in Hong Kong. In June, 2007, Hony Capital invested in CSPC Pharmaceutical Group Limited.
www.digitalchina.comDigital China Holdings Limited
Digital China (861.HK) is a leading IT products distributor and IT services provider in China. Headquartered in Beijing, Digital China is operated in 3 main regions with 19 branches and over 30 representative offices all over China, covering Major Account, Enterprises, Small Medium Enterprises (SME), Small Office Home Office (SOHO) and Consumers (End Users) sectors, etc. The company has enjoyed the No.1 status in national system service business and supply chain service market for over ten years. In August 2007, Hony Capital invested in Digital China.
www.longhao.com.cnShenzhen Longhao World Business Development Company Limited
Founded in 1987, Longhao is a leading middle-to-high-end casual footwear company. Its major business is to design and sell footwear with its own brands such as SKAP, SKAP Woman, Dragonsea, and Morresi. The company has developed a national distribution network of over 500 outlets located in top tier airports, premium department stores and shopping malls. In September 2007, Hony Capital invested in Longhao.
www.lenovomobile.comLenovo Mobile Telecom Technological Company
Lenovo Mobile is a leading mobile handset producer in China and ranks No.4 after Nokia, Motorola and Samsung. The company owns wide spectrum products ranging from 2.5G feature phone, smart phone to 3G handset products. In January 2008, Hony Capital invested in Lenovo Mobile.
www.cgtg.com.cnNew Century Department Store
The company is a leading regional department store and supermarket chain with a well-recognized brand in Chongqing, China. At the end of 2007, the company had 11 department stores and 57 supermarkets nationwide which are highly recognized by local customers. In June 2008, Hony Capital invested in New Century Department Store.
www.cifa.comCompagnia Italiana Forme Acciaio S.p.A.
CIFA is a worldwide leading concrete machinery manufacturer and the largest one in Italy with around 70-80% market share in Italy. In west Europe, CIFA takes 23% and 20% market share in mixers and pumps respectively, and takes 16% in both mixers and pumps in its core market, which includes west Europe, east Europe and Middle East/Africa. Hony Capital has teamed with other co-investors as financial sponsors for Zoomlion to acquire 100% equity stake of CIFA. In September 2008, Hony Capital invested to CIFA.
www.jsxhsd.comJiangsu Xinhua Distribution Group
Jiangsu Xinhua Bookstore Group Co., Ltd is specialized in book distribution, and is the market leader for seventeen consecutive years. As a nationwide large-scale cultural media enterprise with an annual sales of nearly RMB 4 billion Yuan, Jiangsu Xinhua was jointly evaluated as “Excellent Enterprise in National Reform of Cultural System Reform” by four ministries and commissions such as the Central Propaganda Department and the State Press and Publication Administration in 2008; ranked 173rd among “Top 500 of Chinese Service Enterprises in 2008” by China Enterprise Directors Association, taking the first place amongst cultural media enterprises. Mr. Tan Yue, President of Jiangsu Phoenix Publishing & Media Group, the holding company of Jiangsu Xinhua Distribution Group, was rewarded as "2009 Annual Economic Professionals" by CCTV. In May, 2008, Hony Capital invested in Jiangsu Xinhua Bookstore Group Co., Ltd. On June 30, 2009, Jiangsu Xinhua Bookstore Group Co., Ltd was completely converted into a company limited by shares with the name changed as Jiangsu Phoenix Xinhua Book Industry Co., Ltd.
www.yaohua-glass.comChina Yaohua Glass Group Corporation
China Yaohua Glass Group Corporation, one of top ten of the sheet glass manufacturers in China, is the only enterprise specialized in design of glass production line and construction, R&D, production, processing of glass products and production of Low-E and Sun-E glasses in batch. In June, 2008, Hony Capital invested in China Yaohua Glass Group Corporation.
www.happigo.comHappigo
Founded at the end of 2005, invested by Hunan Broadcasting System with millions of funds, Happigo Home Shopping Co., Ltd opened to operate in March 2006, starting with “TV Stores and Chain Operation”, positioning as “Media Retailer and E-commerce”, dedicated to the development crossing industries, media and regions; offering almost 6000 species of high-end commodities in 18 categories through the channels of TV, internet, catalog, telephone outbound systems, mobiles and broadcasting stations. Happigo has become a leader in its industry based on its speed of development, market scale and brand reputation. On 31, March, 2010, Hony Capital invested in Happigo.
www.lzfrp.comZhongfu Lianzhong Composites Group
Belonging to China Composites Group Corporation under China National Building Material Group Corporation, Lianyungang Zhongfu Lianzhong Composites Group combines R&D, design, production and services with regard to composite products and is a key national high-tech enterprise producing rotor blades, pipes, tanks, and high-pressure cylinders and pipes as its main products, and the top manufacture of rotor blades for aero-generator. In May, 2008, Hony Capital invested in Zhongfu Lianzhong Composites Group.
Copyright @ 2010 Hony Capital (Beijing) Co., Ltd. All Rights
|
| Useful To Me Not Useful To Me | |
|
gbleng
Member |
12-Oct-2010 15:21
|
|
x 0
x 0 Alert Admin |
chinese capitalists to unlock the the china market.... approval coming...????? |
| Useful To Me Not Useful To Me | |
|
JustForFun
Member |
12-Oct-2010 14:47
|
|
x 0
x 0 Alert Admin |
You are right....Mr Loh sold off all his holdings. |
| Useful To Me Not Useful To Me | |
|
allright
Senior |
12-Oct-2010 14:38
|
|
x 0
x 0 Alert Admin |
Does this mean Mr Loh has sold off all his holdings?What does this mean for the company? |
| Useful To Me Not Useful To Me | |
|
JustForFun
Member |
12-Oct-2010 14:28
|
|
x 0
x 0 Alert Admin |
Hony Capital To Become A Major Shareholder Of Biosensors International Group, Ltd., A Leading Global Medical Device Company On October 10, 2010, Hony Capital, through its wholly‐owned special purpose vehicle, Autumn Eagle Limited entered into a Sale and Purchase Agreement with Mr Yoh‐Chie Lu, the Chairman of Biosensors International Group, Ltd. (“Biosensors”) and as trustee of a living trust established for the benefit of Mr Lu and his spouse and Lu Asset Management L.P. (a limited partnership established for the benefit of Mr Lu, his spouse and his brother) to acquire 197,326,100 issued ordinary shares in the capital of Biosensors at S$0.8888 per share after taking into consideration the average price of the shares of Biosensors traded on the Singapore Stock Exchange for the 45‐day period prior to the date of Sale and Purchase Agreement. “Hony Capital is excited to become a shareholder of Biosensors. We have been following the developments at Biosensors for some time, and we recognize Biosensors as a leading global medical device company in the cardiology industry equipped with superior products, strong R&D capabilities and an extensive market footprint. We see there is tremendous growth potential in the market it serves, particularly in emerging markets like China, as cardiac disease remains the No. 1 cause of death in China. As a long‐term investor, Hony Capital has asked Mr Lu to stay on as Chairman of Biosensors so we can jointly develop new strategic initiatives. Hony Capital looks forward to working with Biosensors’ shareholders and management team to add value strategically and operationally thus enabling Biosensors to realize its true value in the future”, said John Zhao, CEO of Hony Capital. In addition, Hony Capital has purchased separately on the same date in aggregate 121,986,100 shares from other vendors, bringing its total shareholding in Biosensors to 29.47%. “I have decided to sell my shares to Hony Capital which will serve as a valuable strategic investor of Biosensors and help it achieve its true value going forward. I am very excited because the new major shareholder, Hony Capital is one of the most reputable private equity firms in Asia particularly in China. Biosensors continues to own 50% of JWMS in China and together with our other assets in the rest of the world, the interests of Hony Capital and Biosensors are totally aligned with all other Biosensors’ shareholders with the objective of maximizing value creation from our assets. With this transaction, Hony Capital becomes the largest shareholder (29.47% stake) of Biosensors. We are especially optimistic that Hony Capital will assist Biosensors to enhance our value in China particularly leveraging upon its financial strength, market experience and expertise thus helping us to continue to grow in China and throughout the world. In spite of the sale of my shares, I will remain as Chairman of Biosensors and intend to work with our new partner to lead the Company into a fresh period of transformative growth. As the founder of the Company, I am proud of how far the Company has grown and risen in the last 20 years. I am confident that Hony Capital will help bring the Company to even greater heights”, added Mr Lu. Hony Capital is a China‐focused middle‐market private equity firm, employing a “value creation” investment philosophy to increase the financial performance and value of its portfolio companies. With over USD 3 billion in assets under management across five funds, Hony Capital primarily focuses on construction materials, pharmaceuticals and healthcare, construction machinery and consumer & retails industries. Hony Capital’s secondary industry focus is on media & entertainment, financial services, and energy & resources. |
| Useful To Me Not Useful To Me | |